All three companies closed out the year, which saw significant growth in mergers and acquisitions, with high-value deals that could potentially set the tone for M&A in 2024.
Tag Archive for: Roche
The investigational allogeneic CAR-T therapy P-BCMA-ALLO1 appears to be more effective following strong immunosuppressive preconditioning.
Several big-name drugmakers are weighing in on the opportunity in the weight-loss drugs market.
The regulator placed a partial clinical hold on Roche’s fenebrutinib—being developed for relapsing MS—after two patients experienced elevated hepatic transaminase and bilirubin levels indicative of liver injury.
The acquisition will give Roche access to Carmot’s clinical portfolio of three GLP-1 receptor agonists, placing it squarely in the middle of the competition to treat overweight and obesity.
The blood-brain barrier: It’s neuroscience’s next frontier, and a presentation on Roche’s trontinemab at the Clinical Trials on Alzheimer’s Disease conference last month sparked new optimism that researchers might be getting close to breaking through it.
Roche and its subsidiaries Genentech and Chugai Pharmaceutical jointly told the court without providing further details that they, Biogen and its manufacturer Bio-Thera had agreed to settle the case.
The Swiss drugmaker’s new chief executive Thomas Schinecker is keen to restore Roche’s battered drug development record after major late-stage trial setbacks in Alzheimer’s and cancer immunotherapy last year.
The pipeline culling comes as Roche sustains a slight dip in sales. From January to September 2023, the pharma group made over $49 billion, compared with $52.48 billion during the same period in 2022.
Early stage ALK-positive non-small cell lung cancer patients treated with Roche’s Alecensa saw an “unprecedented” 76% drop in the risk of recurrence or death, the company announced.
